Catalyst Pharmaceuticals, Inc.
CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment ofā¦ read more
Healthcare
Biotechnology
19 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$24.76
Price+4.12%
$0.98
1Y
Price
Market Cap
$3.043b
Mid
Price/Earnings 3y Avg5y Avg
14.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+53.1%
EBITDA Margin+34.5%
Net Profit Margin+29.4%
Free Cash Flow Margin+53.1%
EBITDA Margin+34.5%
Net Profit Margin+29.4%
Free Cash Flow MarginRevenue
$588.989m
+19.8%
1y CAGR+43.1%
3y CAGR+45.3%
5y CAGREarnings
$214.326m
+30.8%
1y CAGR+48.7%
3y CAGR+64.2%
5y CAGREPS
$1.68
+28.2%
1y CAGR+40.1%
3y CAGR+55.7%
5y CAGRBook Value
$954.268m
$1.107b
Assets$152.543m
Liabilities$2.787m
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
$208.612m
-12.8%
1y CAGR+75.8%
3y CAGR+80.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company